1stOncology™: Cancer Intelligence Service – Page 10450 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment

On November 4, 2019 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, reported that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO), granting the Company a new patent covering the combination of AsiDNA, Onxeo’s first-in-class DDR inhibitor, with any PARP inhibitor (PARPi) for cancer treatment, in the United States (Press release, Onxeo, NOV 4, 2019, View Source [SID1234550269]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Onxeo was granted a corresponding patent in Europe in December 2018. The new U.S. patent, is valid until 2036. It further expands Onxeo’s intellectual property portfolio for AsiDNA, which now includes 168 number of patents globally.

"Cancer therapeutic resistance is one of the most significant challenges for successful treatment. Therefore, fighting acquired resistance has become a key focus for researchers and clinicians around the world. Our translational studies of AsiDNA have demonstrated its significant potential in combating cancer therapeutic resistance to both DNA-damaging agents and targeted therapies such as PARPi. This new patent, which expands the protection of the combination of AsiDNA with any PARP inhibitor to the leading U.S. market, further supports the initiation of a new clinical study in the coming months that is designed to validate this very unique effect of AsiDNA on the acquired resistance to a PARPi," said Judith Greciet, Chief Executive Officer of Onxeo.

Onxeo has conducted an extensive preclinical program with AsiDNA in combination with various PARPi in several cancer models, such as triple negative breast cancer and small-cell lung cancer. In addition to demonstrating the strong synergistic effect of the combination, even in cancer cells non-sensitive to PARPi alone, the translational studies have shown the ability of AsiDNA to prevent the onset of tumor resistance to PARPi and even abrogate an acquired resistance. This property will be further evaluated in the upcoming Phase 1b clinical study of AsiDNA in combination with a PARP inhibitor in advanced ovary cancer.

Upcoming events

November 6, 2019
"Direct Dirigeants" Event

Paris, France

November 12-13, 2019
Bryan, Garnier & Co European Healthcare Conference

Paris, France

November 12-15, 2019
Tides Europe 2019

Amsterdam, Holland

January 29-31, 2020
PARP & DDR inhibitors Summit 2020

Boston, MA, USA

March 2-4, 2020
TAT 2020 International Congress on Targeted Anticancer Therapies

Paris, France

March 30-April 1st, 2020
DNA Damage Responses and Cancer

Cambridge, UK

April 24-29, 2020
AACR Annual Meeting 2020

San Diego, CA, USA

ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer

On November 4, 2019 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported the appointment of Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer (Press release, ACADIA Pharmaceuticals, NOV 4, 2019, View Source [SID1234550268]). Dr. Subbiah will report to Serge Stankovic, M.D., M.S.P.H., ACADIA’s President and be responsible for corporate medical affairs including medical strategy, scientific communications, and medical science liaison activities.

"I am very excited to welcome Ponni to our executive team. Her extensive experience as a clinician and pharmaceutical physician as well as her strong leadership track record in global medical and scientific affairs, are extremely valuable at this transformational time for our organization," said Dr. Serge Stankovic.

"ACADIA has transformed treatment of patients with Parkinson’s disease psychosis and has the potential to also play a crucial role in how we continue to improve the lives of patients with other CNS disorders," said Dr. Subbiah. "I am excited to join ACADIA on this journey and use my relevant medical affairs and clinical development experience to advance the company’s strong portfolio of approved and investigational programs for some of today’s biggest challenges in neuro health."

Dr. Subbiah is a neurologist with over 20 years of experience in the pharmaceutical industry and global health sector. She has led the development and execution of medical and clinical research strategies in various therapeutic areas, including neurology, psychiatry, opioid addiction, pain, oncology, diabetes, urology, inflammation, respiratory, and infectious diseases.

Dr. Subbiah was most recently Chief Medical Officer for Indivior Inc., with responsibility for pharmacovigilance and medical affairs globally. She was also the company spokesperson at policy discussions including testifying at the Presidential Commission on Combating Drug Addiction and Opioid Crisis and the hearing by the House Committee on Energy & Commerce on the opioid crisis. During her previous tenure of over 15 years at Pfizer, Inc., she held various leadership roles in global medical affairs and led Pfizer’s Global Access program to improve healthcare access for low-income populations in the developing world through approaches that were commercially viable and sustainable.

Dr. Subbiah received her medical degree from Madras Medical College in Chennai, India and completed a residency in neurology at the Mayo Graduate School of Medicine in Rochester, MN. She completed a research/clinical fellowship in AIDS Neurology at Johns Hopkins University School of Medicine and earned a Master’s degree in Public Health from the Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.

Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference

On November 4, 2019 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time (Press release, Seattle Genetics, NOV 4, 2019, View Source [SID1234550267]). The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Immunomic Therapeutics Announces Presentations at Upcoming Scientific and Medical Conferences

On November 4, 2019 Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, reported that Immunomic scientists will present data from its oncology programs at the following scientific and medical conferences (Press release, Immunomic Therapeutics, NOV 4, 2019, View Source [SID1234550266]).

"The data to be presented at the conferences will show the broad promise of Immunomics’ pipeline and the productivity of our UNITE proprietary technology platform," said Dr. Teri Heiland, Chief Scientific Officer. "We are committed to advancing our research into the clinic for patients in the years ahead."

Upcoming Medical & Scientific Conferences:

SITC (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)) 34th Annual Meeting
Title: Lysosomal-associated membrane protein-1-targeting of a poly-neoepitope DNA vaccine elicits potent immune responses and inhibits tumor growth
Presentation Date: Saturday, November 9th 7:00 am – 8:30 pm Eastern Time
Location: Poster Hall (Prince George AB), Gaylord National Hotel and Convention Center, National Harbor, Maryland
International Conference on Vaccines Research & Development
Title: Rapid activation of antigen-specific CD4 T cells by HER2-UNITE therapeutic vaccine suppresses tumor growth and prolongs survival
Presentation Date: Tuesday, November 19th at 10:55 a.m. – 11:20 a.m. Eastern Time
Location: Session-I Cancer Vaccines | Immunotherapy & Immunodominance, HALL-A, Crowne Plaza Boston, Newton, Boston
2019 Society for Neuro-Oncology Annual Meeting
Title: CMV-Based Plasmid DNA Vaccine for GBM Using the UNITE Platform
Presentation Date: Friday November 22, 2019 at 4:30 p.m. Eastern Time
Location: Concurrent Session 2C: Drug Discovery/Drug Resistance and Experimental Therapeutics (2C), JW Marriott Desert Ridge, Phoenix, Arizona

Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

On November 4, 2019 Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is reported lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month (Press release, Genprex, NOV 4, 2019, View Source [SID1234550265]).

Each patient’s cancer is unique, but there are some preventive efforts that can be made to lower the risk of getting lung cancer. The following are preventive actions that may lower the risk of getting lung cancer:

Do not smoke, or if you smoke, then quit smoking – Tobacco, cigarettes and other smoking products all increase the risk of lung cancer.
Reduce your exposure to secondhand smoke – People who inhale secondhand smoke are exposed to the same cancer-causing agents as smokers, but at a reduced amount.
Reduce your exposure to radon – Have your home tested and treated for high radon levels, which can cause lung cancer.
Know your family’s history with lung cancer – If you have a family history of lung cancer, then you are at an increased risk of getting lung cancer.
According to the World Health Organization, lung cancer is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver, prostate or skin cancers, and lung cancer is one of the most common types of cancer. Each year, there are more than 2 million new lung cancer cases and 1.7 million deaths from lung cancer worldwide.

The American Cancer Society’s 2019 report states that each year in the United States there are more than 228,000 new cases of lung cancer and more than 142,000 deaths from lung cancer. NSCLC represents 84 percent of all lung cancers and has a 23 percent five-year relative survival rate. However, according to the National Cancer Institute, 57 percent of lung cancer diagnoses are distant, or have metastasized, and the five-year relative survival rate for distant diagnoses is less than 5 percent.

LUNGevity Foundation points out that 10-15 percent of lung cancer cases are in never smokers, and it is possible to get lung cancer even if you have never smoked.

Genprex is working to put an end to this deadly disease. The company is developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC).